Concord Biotech Limited (NSE:CONCORDBIO)

India flag India · Delayed Price · Currency is INR
1,893.90
-26.60 (-1.39%)
Jul 18, 2025, 3:29 PM IST
11.28%
Market Cap198.13B
Revenue (ttm)12.00B
Net Income (ttm)3.72B
Shares Out104.62M
EPS (ttm)35.52
PE Ratio53.32
Forward PE43.70
Dividend10.70 (0.56%)
Ex-Dividend Daten/a
Volume142,352
Average Volume199,302
Open1,925.00
Previous Close1,920.50
Day's Range1,885.10 - 1,939.00
52-Week Range1,345.00 - 2,664.00
Betan/a
RSI58.31
Earnings DateAug 13, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1984
Employees 1,377
Stock Exchange National Stock Exchange of India
Ticker Symbol CONCORDBIO
Full Company Profile

Financial Performance

In 2024, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.

Financial Statements

News

There is no news available yet.